Mia's Feed
Medical News & Research

Artificial Intelligence Enhances Speed and Precision in Autism and ADHD Diagnosis

Artificial Intelligence Enhances Speed and Precision in Autism and ADHD Diagnosis

Share this article

Innovative AI techniques are accelerating and improving the accuracy of autism and ADHD diagnoses through quantitative biomarker analysis, enabling faster assessments and personalized treatment planning.

2 min read

Recent advancements in artificial intelligence (AI) are revolutionizing the diagnosis process for neurodivergent conditions such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). Traditionally, diagnosing these disorders can take up to 18 months due to the reliance on subjective assessments, clinical interviews, and behavioral surveys, which often lack standardized biological markers.

A groundbreaking study led by researchers at Indiana University introduces a data-driven approach that leverages AI to identify quantifiable biomarkers and biometric data, significantly reducing diagnostic time to approximately 15 minutes. This innovative method involves analyzing minute movement patterns with sensors attached to participants' hands while performing simple reaching tasks. These sensors capture high-definition kinematic data, including acceleration, rotation, and linear movements, which reveal subtle differences in motor control between neurotypical individuals and those with ASD or ADHD.

The research builds on earlier work from 2018, where the team discovered movement biomarkers imperceptible to the naked eye but measurable with sensors. Using advanced deep learning algorithms, they assessed movement irregularities that correlate with the severity of neurodivergent disorders. This approach offers a new set of objective biomarkers, enabling clinicians to evaluate how serious a condition is and monitor treatment effectiveness.

While the AI-powered diagnostics are designed to augment, not replace, professional clinical assessments, they could serve as valuable tools for early screening and triage in educational and clinical settings. For example, schools could utilize this technology to identify students who may need further evaluation and intervention, facilitating earlier support and care.

The development of these quantitative tools aims to provide a more standardized and reliable method for diagnosing autism and ADHD, ultimately leading to more personalized and effective treatments. By quantifying movement irregularities and employing deep learning, healthcare providers can better understand the severity of neurodivergent conditions and tailor interventions accordingly.

For more details, refer to the original study published in Scientific Reports: Khoshrav P. Doctor et al, Deep learning diagnosis plus kinematic severity assessments of neurodivergent disorders, 2025.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

How to Avoid, Identify, and Treat Insect Bites During Summer

Learn how to identify, treat, and prevent common insect bites during summer to enjoy outdoor activities safely and avoid health complications.

Stanford Develops ChatEHR: AI Tool That Enables Clinicians to Interact with Medical Records Via Chat

Stanford introduces ChatEHR, an AI-powered software that enables healthcare providers to interact with patient records via chat, streamlining clinical workflows and improving patient care efficiency.

Reinstatement of Hundreds of Laid-Off CDC Employees Marks a Shift in Public Health Workforce

Over 460 CDC employees who were laid off earlier this year are now being reinstated, signaling a shift in federal public health staffing. Learn more about the ongoing impact on CDC programs and operations.

Combining Therapies to Overcome Treatment Resistance in Aggressive Breast Cancer

New research highlights a combination therapy approach that could prevent metastasis and overcome treatment resistance in aggressive triple-negative breast cancer, paving the way for advanced clinical trials.